RANZCP homepage
Jurgen Gotz
Presenters
Professor Jurgen Gotz
Jurgen is the Lesleigh Green - Bill and Nancy Green Endowed Chair in Dementia Research and the inaugural Director of the Clem Jones Centre for Ageing Dementia Research at the University of Queensland’s ‘Queensland Brain Institute’. Gotz studied biochemistry in Switzerland and earned his PhD in immunology with Nobel Laureate Kohler in Germany. After postdoctoral work at UCSF and at Novartis, he became a group leader in Zurich, before moving to the University of Sydney in 2005, and then to the University of Brisbane in 2012. A major focus of his laboratory is to gain insight into how tau and amyloid-beta contribute to Alzheimer’s disease. Over the last decade, the laboratory has also contributed to developing therapeutic ultrasound into a treatment modality for Alzheimer’s disease and other brain diseases, both by transiently opening the blood-brain barrier and as a neuromodulatory tool. Together with his team, Professor Gotz has built an investigational ultrasound device, and a first-in-human safety trial is currently being conducted in Alzheimer patients. Professor Gotz has published more than 230 papers in leading journals including Cell, Science and Neuron, and has authored many authoritative reviews in the Nature Reviews journal family.
Jurgen is the Lesleigh Green - Bill and Nancy Green Endowed Chair in Dementia Research and the inaugural Director of the Clem Jones Centre for Ageing Dementia Research at the University of Queensland’s ‘Queensland Brain Institute’. Gotz studied biochemistry in Switzerland and earned his PhD in immunology with Nobel Laureate Kohler in Germany. After postdoctoral work at UCSF and at Novartis, he became a group leader in Zurich, before moving to the University of Sydney in 2005, and then to the University of Brisbane in 2012. A major focus of his laboratory is to gain insight into how tau and amyloid-beta contribute to Alzheimer’s disease. Over the last decade, the laboratory has also contributed to developing therapeutic ultrasound into a treatment modality for Alzheimer’s disease and other brain diseases, both by transiently opening the blood-brain barrier and as a neuromodulatory tool. Together with his team, Professor Gotz has built an investigational ultrasound device, and a first-in-human safety trial is currently being conducted in Alzheimer patients. Professor Gotz has published more than 230 papers in leading journals including Cell, Science and Neuron, and has authored many authoritative reviews in the Nature Reviews journal family.
